WebDisclosure WebDisclosure
Basculer en Français
10656 Companies
226865 Keywords
155334 Articles
120137 Press releases
Headlines Articles Press releases Wi2Wi Corp. Remove
  1. Home
  2. Companies
  3. Wi2Wi Corp.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 11/18/2025 at 15:05, 7 months 11 days ago

    Wi2Wi Corporation publie ses résultats financiers du troisième trimestre 2025 et annonce un changement de PDG.

    Résultats Financiers Croissance Des Revenus Wi2Wi Transition Du Leadership Sue Amarin
  • PRESS RELEASE

    published on 11/18/2025 at 15:00, 7 months 11 days ago

    Wi2Wi Corporation Announces Third Quarter 2025 Financial Results and Leadership Transition

    Wi2Wi Corporation reported Q3 2025 financial results with revenue up by 3%. CEO Ted Clark steps down, Sue Amarin appointed. Financial details and leadership transition discussed
    Financial Results Leadership Transition Wi2Wi Corporation Ted Clark Sue Amarin
    Logo of Wi2Wi Corp.
Previous page
1 2
Accesswire
  • Published on 06/30/2026 at 05:30, 35 minutes ago

    Nano One Renews At-The-Market Equity Program

  • Published on 06/30/2026 at 02:00, 4 hours 5 minutes ago

    MedMira Reports Third Quarter Results FY2026

  • Published on 06/30/2026 at 00:05, 6 hours ago

    American Critical Minerals Announces Completion of Warrant Exercise Incentive Program

  • Published on 06/29/2026 at 23:46, 6 hours 19 minutes ago

    1933 Industries Reports Third Quarter 2026 Financial Results

  • Published on 06/29/2026 at 22:01, 8 hours 4 minutes ago

    AIP Realty Trust Announces Voting Results of Annual General and Special Meeting of Unitholders

View all ACCESSWIRE
EQS Group
  • Published on 06/29/2026 at 22:47, 7 hours 18 minutes ago

    Correction d’un communiqué du 29.06.2026 22:05 CET/CEST - ABIVAX: Résultats positifs de la partie 2 de maintenance ABTECT démontrant bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les ...

  • Published on 06/29/2026 at 22:05, 8 hours ago

    ABIVAX: Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité

  • Published on 06/29/2026 at 22:05, 8 hours ago

    Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database

  • Published on 06/29/2026 at 20:30, 9 hours 35 minutes ago

    Shelly Group SE: Annual General Meeting approves dividend of EUR 0.13 per share – shareholders approve all agenda items

  • Published on 06/29/2026 at 20:00, 10 hours 5 minutes ago

    IGEL Appoints James Millington as Field CTO for Healthcare in EMEA

View all EQS
Les Echos
  • Published on 06/29/2026 at 18:30, 11 hours 35 minutes ago

    Accor and H World Group expand long-term partnership across direct booking and loyalty platforms

  • Published on 06/29/2026 at 18:30, 11 hours 35 minutes ago

    Accor et H World Group : extension du partenariat de long terme aux plateformes de réservation directe et de fidélité

  • Published on 06/29/2026 at 17:45, 12 hours 20 minutes ago

    Successful issue of a € 1.5 billion bond

  • Published on 06/29/2026 at 17:45, 12 hours 20 minutes ago

    Succès de l’émission obligataire de 1,5 milliard d’euros

  • Published on 06/29/2026 at 17:45, 12 hours 20 minutes ago

    Déclaration hebdomadaire de rachat d'actions

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy